SBIO was created on 2014-12-31 by ALPS. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 156.14m in AUM and 84 holdings. SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.